Stealth BioTherapeutics’ (NASDAQ:MITO) lock-up period will expire on Wednesday, August 14th. Stealth BioTherapeutics had issued 6,500,000 shares in its initial public offering on February 15th. The total size of the offering was $78,000,000 based on an initial share price of $12.00. After the end of Stealth BioTherapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
A number of equities research analysts have recently issued reports on MITO shares. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Stealth BioTherapeutics in a report on Friday, July 12th. Zacks Investment Research downgraded shares of Stealth BioTherapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Stealth BioTherapeutics presently has a consensus rating of “Buy” and a consensus price target of $24.83.
Shares of MITO opened at $12.24 on Tuesday. The company has a 50 day moving average of $12.28. The stock has a market capitalization of $428.77 million and a P/E ratio of -8.68. Stealth BioTherapeutics has a 1-year low of $10.70 and a 1-year high of $20.99.
A hedge fund recently bought a new stake in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC bought a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITO) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned approximately 0.18% of Stealth BioTherapeutics at the end of the most recent reporting period. 0.87% of the stock is currently owned by institutional investors.
About Stealth BioTherapeutics
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
Recommended Story: What member countries make up the G-20?
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.